Chemotherapy for advanced gastric cancer (Q24244040)

1

0 references

Winfried WG Grothe

2

0 references

Susanne Behl

3

0 references

Gerhard GK Kleber

4

0 references

Axel AG Grothey

5

0 references

Wolfgang E. Fleig

Cochrane Database of Systematic Reviews

7

0 references

publication date

20 April 2005

0 references

published in

0 references

cites work

A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

Phase II trial of UFT in advanced colorectal and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Sequential and combination chemotherapy of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumor study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Estimating the world cancer burden: Globocan 2000.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Histologic types of gastric carcinoma in high- and low-risk areas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized study with mitomycin C + 5-fluorouracil+cytosine arabinoside (MFC)+5-fluorouracil, MFC+tegafur and uracil (UFT), and MF+UFT in advanced gastric cancer: interinstitutional differences in a multicenter study in Japan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

How should meta-regression analyses be undertaken and interpreted?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Docetaxel in combination for advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Chemotherapy of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Palliative Care: the World Health Organization's global perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Gastric cancer epidemiology and risk factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Thirty years of Medical Research Council randomized trials in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Cancer of the esophagogastric junction: epidemiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

One-year survey of carcinoma of the oesophagus and stomach in Wales

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Epidemiology of upper gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Extended lymph-node dissection for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Irinotecan in the treatment of gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Docetaxel-based chemotherapy in the treatment of gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Etoposide (E) + epirebicin (E) + cisplatin (P) combination chemotherapy (EEP) In advanced gastric cancer: Negative impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomised trial of epirubicin versus fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

The decline in gastric cancer: epidemiology of an unplanned triumph

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Combination chemotherapy in advanced gastrointestinal malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Mitomycin therapy in gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Doxorubicin and 5-fluorouracil versus doxorubicin and oral ftorafur in in the treatment of advanced gastric cancer--a phase II and III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021

Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004064.PUB2

7 January 2021